Oncolysin S

Drug Profile

Oncolysin S

Alternative Names: N901-blocked ricin; N901-BR

Latest Information Update: 25 Nov 1998

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ImmunoGen
  • Developer Dana-Farber Cancer Institute; ImmunoGen
  • Class Immunotoxins; Monoclonal antibodies
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Small cell lung cancer

Most Recent Events

  • 25 Nov 1998 Discontinued-II for Small cell lung cancer in Switzerland (Infusion)
  • 25 Nov 1998 Discontinued-II for Small cell lung cancer in USA (Infusion)
  • 10 Apr 1997 A study has been added to the pharmacodynamics, therapeutic trials and adverse events sections
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top